“Our practice provides critical support to our life sciences and healthcare clients, who continue to turn to Goodwin for our industry expertise and integrated platform,” said Deborah Birnbach, co-chair of Goodwin’s Complex Litigation and Dispute Resolution practice. “William’s broad-based life sciences and healthcare experience will be an invaluable asset to our clients as we continue to add strength to our bench of industry specialists.”
Jackson’s litigation practice focuses primarily on the life sciences and healthcare sectors. He has successfully represented both plaintiffs and defendants in intellectual property cases, Hatch-Waxman litigation, class actions, contractual disputes, and other high-stakes commercial matters before U.S. federal and state courts, and domestic and international arbitration tribunals. In addition to representing clients in litigation, Jackson often provides litigation risk analysis, counseling, and strategic advice.
“Goodwin is the go-to firm for life sciences and healthcare companies, providing a true one-stop shop for innovators and investors throughout the corporate lifecycle,” said Jackson. “I’m thrilled to join a team of world-class litigators as we provide counsel on some of the most complex, high-stakes challenges these industries face.”U.S. News — Best Lawyers’ 2021 edition named Goodwin the Biotechnology Law Firm of the Year for the sixth time. LMG Life Sciences also named Goodwin firm of the year for 2020 in the corporate, lifecycle, and intellectual property categories, and has named Goodwin the Hatch-Waxman litigation firm of the year for several years. Mergermarket’s Deal Drivers FY20 reports named Goodwin the number one firm (by deal count) for Pharma, Medical, and Biotech M&A in North America, and the number two firm (by value) for Pharma, Medical, and Biotech M&A in Europe, the Middle East, and Africa. Pitchbook’s latest full-year league tables named Goodwin the number three most active in global venture capital deals for pharma and biotech, the number four most active in global private equity — healthcare deals, and the number four most active in global venture capital deals for healthcare devices, supplies, services, and systems.